No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Grants Priority Review of AZ/Daiichi Sankyo’s Enhertu®
AstraZeneca and Daiichi Sankyo announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Enhertu® (trastuzumab deruxtecan) and has granted Priority Review to treat patients with unresectable or metastatic HER2-positive...